Cargando…
Ixazomib-induced Sweet’s syndrome: A case report
Ixazomib, a proteasome inhibitor commonly used for the treatment of multiple myeloma, is a rare cause of Sweet’s syndrome. We present a 62-year-old man who developed drug-induced Sweet’s syndrome during his fifth cycle of ixazomib for treatment of refractory multiple myeloma. Monthly rechallenge led...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278404/ https://www.ncbi.nlm.nih.gov/pubmed/37342419 http://dx.doi.org/10.1177/2050313X231181034 |